Calroy Health Sciences | 1-800-609-6409

Research papers are made available to registered licensed health care practitioners only.

Please Log In in order to view this content!

IMPORTANT NOTICE: The information on this webpage is for licensed healthcare practitioner education only, and is not to be disseminated to the general public.


A brief summary of studies of Arterosil, a specific glycocalyx regenerating compound (GRC) for the restoration of endothelial function and regression of atherosclerotic plaque.

Three types of studies are reported: cellular, animal and human. Each study focused on a different effect of Arterosil, a nutraceutical that contains a patent-pending endothelial glycocalyx regenerating compound (GRC).

Atherosclerotic Plaque Regression Study Hospital in Beijing — Human Pilot (still underway)
Preliminary Findings to Date: 47% and 64% regression of atherosclerotic plaque lipid-rich necrotic core (LRNC) in 60 days

*These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure or prevent any disease.

U.S. and International Patents Pending